Levetiracetam Tablet
Product Images NDC 80425-0565

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 80425-0565). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam 500mg #120 (Levetiracetam 500mg Tablet 80425 0565 01)

FDA Label Image

Levetiracetam 500mg #30 (Levetiracetam 500mg Tablet 80425 0565 02)

This is a description of Levitiracetam 500mg tablets in a pack of 30 units. It includes details such as the NDC code, Lot number, expiration date, and source NDC. The tablets are a generic version of KEPPRA, manufactured by TRIS PHARMA INC and can only be dispensed with a prescription.*

FDA Label Image

Levetiracetam 500mg #60 (Levetiracetam 500mg Tablet 80425 0565 03)

This is a description of Leveteracetam 500mg tablet, which is a prescription medication. It is available in a pack of 60 tablets. The medication is compared to Keppra and has an expiration date of 12/31/2030. The manufacturer is Tris Pharma Inc. This information also includes the National Drug Code (NDC) numbers for reference.*

FDA Label Image

Levetiracetam 500mg #90 (Levetiracetam 500mg Tablet 80425 0565 04)

This is a description of Levitiracetam 500mg tablet bottle containing 90 tablets. The NDC or National Drug Code for this medication is 80425-0565-04. The lot number is XXXXXX and the expiration date is 12/31/2030. The source NDC is 27808-0264-01. This medication is manufactured by Tris Pharma Inc. This medicine is available a prescription medication.*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

FDA Label Image

Figure1 (Levetiracetam Tablets 2)

This is a comparison of the effectiveness of a placebo and two different doses of Levetiracetam (1000 mg/day and 3000 mg/day) in treating patients. The study involved 95 patients in the placebo group, 97 patients in the 1000 mg/day Levetiracetam group, and 101 patients in the 3000 mg/day Levetiracetam group. The data present the percentage of patients in each group and can be used to evaluate the efficacy of the different treatments.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

This text seems to provide information about the percentage of patients and the number of participants in a medical trial involving a placebo and levetiracetam at a dosage of 2000 mg daily. The data shows that 63% of patients received placebo while 35.2% received levetiracetam. The study involved 111 participants in the placebo group and 105 participants in the levetiracetam group.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

This text appears to be showing a percentage breakdown for different categories. It also mentions two groups labeled as "Placebo" and "Levetiracetam" with respective sample sizes. The data provided seems to be related to a study or analysis comparing these groups.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.